Collaboration is an essential part of DNDi’s model: we cannot carry out our work without the engagement of public and private partners.
Acting as a ‘conductor of a virtual orchestra,’ we leverage and give value to our partners’ specific assets, capacities, and expertise. At every phase of the R&D process – from drug discovery and pre-clinical research to clinical trials and large-scale implementation studies – DNDi manages the process, creating multiple alliances, strengthening cross-sector networks, and working in close partnership with a broad range of different actors.
Today, DNDi has forged a diverse range of alliances and research collaborations with over 200 partners in nearly 50 countries.
A worldwide footprint anchored in endemic countries
Key statistics on our partnerships
Partner institutions by country income group
Partner institutions by region
Partner institutions by type
*Figures reflect third-party institutions that contributed to a DNDi project or strategic objective in 2024 in at least one of the following ways: (i) in-kind, (ii) as a co-applicant partner to a successful funding application, or (iii) as a facilitator of local ownership of and access to new treatments.
Partnering for patients
Collaboration is an essential part of how we work. We have forged a diverse range of alliances and research collaborations with over 200 partners in nearly 50 countries.
Read, watch, share
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
